Emergency cardiac surgery in patients on oral anticoagulants and antiplatelet medications.
Rami AkhrassAlan Marc GillinovFaisal G BakaeenDeena AkrasScott J CameronJay BishopSamir KapadiaLars G SvenssonPublished in: Journal of cardiac surgery (2021)
Proper knowledge of anticoagulants, their reversal agents, and the usefulness of laboratory testing are all essential. Platelet transfusion remains the mainstay for antiplatelet medications. Four-factor prothrombin complex concentrate is considered in patients on oral anticoagulants if CPB needs to be instituted quickly. Specific reversal agents such as idarucizumab and andexanet alfa can be considered if significant tissue dissection is anticipated, such as redo sternotomy, but are costly and may lead to heparin resistance and anticoagulant rebound.
Keyphrases
- oral anticoagulants
- atrial fibrillation
- end stage renal disease
- cardiac surgery
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- emergency department
- prognostic factors
- venous thromboembolism
- public health
- peritoneal dialysis
- heart failure
- acute kidney injury
- coronary artery disease
- left ventricular